Form 4: Sensei Biotherapeutics Executive Josiah Craver Acquires Stock Options
SEC Form 4 Filing
Principal Financial Officer Josiah Craver of Sensei Biotherapeutics acquired stock options for 50,000 shares on February 14, 2025.
Summary
- Josiah Craver, the Principal Financial Officer of Sensei Biotherapeutics, acquired stock options on February 14, 2025.
- The options grant the right to buy 50,000 shares of common stock at an exercise price of $0.476 per share.
- The options vest over four years, with 25% vesting on February 14, 2026, and the remainder vesting monthly over the subsequent three years, contingent upon continuous service with Sensei Biotherapeutics.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard executive compensation disclosure.
Industry Context
Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of the stock option grant. |
| 02/14/2025 | Date of Form 4 filing. |
| 02/14/2026 | First vesting date for 25% of the stock options. |
| 02/13/2035 | Expiration date of the stock options. |
Keywords
stock options, Sensei Biotherapeutics, Josiah Craver, Form 4, executive compensation, SNSE
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.